Pala.Bo

The company's capital structure is characterized by a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.92, suggesting limited short-term liquidity cushion. Free cash flow is minimal at INR 3,391,000, and capital expenditures are negative at INR -185,780,000, indicating asset disposals or reduced investment in physical capital.

Profitability metrics show a return on equity of 13.86% and a return on assets of 6.07%, both below the industry median for pharmaceutical firms, which typically exceed 15% ROE and 8% ROA. Operating income of INR 197,642,000 and net income of INR 115,189,000 reflect a relatively narrow margin profile, with gross profit at INR 858,077,000 or 45.7% of revenue.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segmentation increases exposure to market-specific risks, particularly in its primary operating region. No material revenue concentration by geography is reported, but the absence of geographic breakdown limits visibility into regional performance.

Growth trajectory is constrained, with no disclosed revenue growth in the current fiscal year. The outlook for the next fiscal year is neutral, with no significant revenue or margin expansion expected. Historical revenue trends show a flat trajectory, with INR 1,877,378,000 in the latest period.

Risk factors include a medium liquidity risk due to a current ratio below 1 and a negative net cash position after subtracting total debt. Dilution risk is low, with no dilutive events disclosed in the latest filings. However, the company's reliance on long-term debt (INR 695,257,000) introduces refinancing risk in a rising interest rate environment.

Recent events include no material earnings calls or regulatory filings in the past quarter. The company has not disclosed any new product launches or strategic acquisitions in the latest financial statements.